StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Stock analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Sunday. The firm set a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Up 5.1 %

Shares of NASDAQ:TNXP opened at $0.24 on Friday. The company has a 50 day moving average of $0.17 and a two-hundred day moving average of $0.62. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $44.95 million, a price-to-earnings ratio of 0.00 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts forecast that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.